A Phase I Open Label Study to Evaluate the Tumor-targeting Properties and Safety of 124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer.

Trial Profile

A Phase I Open Label Study to Evaluate the Tumor-targeting Properties and Safety of 124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Anti-PSCA A11 antibody I-124 (Primary)
  • Indications Bladder cancer; Pancreatic cancer; Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Jun 2017 Status changed from suspended to completed.
    • 26 May 2016 Status changed from recruiting to suspended because PSCA Minibody supply temporarily unavailable.
    • 14 Jan 2016 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2017 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top